PLA2G4A: Cytosolic phospholipase A2
Has primarily calcium-dependent phospholipase and lysophospholipase activities, with a major role in membrane lipid remodeling and biosynthesis of lipid mediators of the inflammatory response.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PLA2G4A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Giripladib | Phase 2 | Wyeth is now a wholly owned subsidiary of Pfizer | Small molecule | InhibitorCytosolic phospholipase A2 inhibitor | 0 |
- Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder0.61
- Gastrointestinal ulceration, recurrent, with dysfunctional platelets0.59
- Kidney disorder0.31
- Diabetes mellitus0.29
- Humerus fracture0.29
- Immune system disorder0.29
- Ankylosing spondylitis0.28
- Frozen shoulder0.28
- Schizophrenia0.27
- Stroke disorder0.27
- Alcohol drinking0.27
- Optic neuritis0.26
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3816, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P47712, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets